Global WholeHealth Partners Corp.
Global WholeHealth Partners Email Alerts: Click to Subscribe
View Company Website: Click to View
Report Link: Initial Research Report (Dated 10/15/2020)
Analyst: Howard Halpern
Taglich Rating: Speculative Buy
Price Target: NA
Time Horizon: NA
Rating Established: October 15, 2020
Price When Established: $1.11
Most Recent Report: October 15, 2020
Price When Issued: $1.11
Global Wholehealth Partners Reports 3Q20 Results
On November 12, 2020, Global Wholehealth Partners filed its 3Q20 10-Q for the three-months ended September 30, 2020.
GWHP reported 3Q20 net loss of $247,000 or breakeven per share, on revenue of $15,000. In the year-ago period the company reported a net loss of $19,000 or breakeven per share on no revenue.
Taglich Brothers did not provide a forecast for 3Q20.
Global WholeHealth Partners Corp., headquartered in San Clemente, CA, was founded to develop, manufacture and market in-vitro and rapid diagnostic tests. The company’s vision is to provide infectious disease diagnostics and molecular solutions that reduce the time to diagnose medical results. The company plans to produce and sell rapid diagnostic tests that include but is not limited to, Corona Viruses including COVID-19, Ebola, ZIKA, Dengue, Malaria, Influenza, and Tuberculosis.
Please view our current disclosure and disclaimer on our most recent research report.